The Global Renal Denervation Market Size accounted for USD 198.1 Million in 2021 and is projected to achieve a market size of USD 4,464.6 Million by 2030 rising at a CAGR of 41.5% from 2022 to 2030. Increasing incidences of hypertension, changing lifestyle, and long-term positive effect of renal denervation procedure are the key factors driving market. Increasing cases of therapy-resistant hypertension is among one of the prime growth-driving factors for the global renal denervation market. Hypertension is a long term medical condition and is among the most common diseases in the world also without any major symptoms.
Renal Denervation Market Report Statistics
- Global renal denervation market revenue is estimated to reach USD 4,464.6 Million by 2030 with a CAGR of 41.5% from 2022 to 2030
- Europe renal denervation market share accounted for over 70% shares in 2021
- According to World Health Organization (WHO), more than 1.1 billion people suffer from hypertension throughout the world
- Asia-Pacific renal denervation market growth will register quick CAGR from 2022 to 2030
- Based on product type, symplicity acquired over 45% of the overall market share in 2021
- Associated beneficial factors will fuel the global renal denervation market value
- Development of new techniques is a popular renal denervation market trend that is fueling the industry demand
The global renal denervation market in developed economies, such as Italy, the U.K., and France, is moderately mature as compared to other developing and under-developed economies attributable to the presence of major companies in these countries and high awareness and demand among the population for such products. Europe constituted the largest share due to the technological advancements and increase in number of drug-resistant hypertension cases in the regional market.
Global Renal Denervation Market Dynamics
Market Drivers
- Increasing prevalence of hypertension
- Long-lasting effect of procedure
- Changing lifestyle of people
- Availability of improved and alternative technology
Market Restraints
- Negative reimbursement and painful procedure
- Strict regulatory framework for these devices
Market Opportunities
- Technological advancement in renal denervation devices
- Growing expenditure on research and clinical activities
Renal Denervation Market Report Coverage
| Market |
Renal Denervation Market |
| Renal Denervation Market Size 2021 |
USD 198.1 Million |
| Renal Denervation Market Forecast 2030 |
USD 4,464.6 Million |
| Renal Denervation Market CAGR During 2022 - 2030 |
41.5% |
| Renal Denervation Market Analysis Period |
2018 - 2030 |
| Renal Denervation Market Base Year |
2021 |
| Renal Denervation Market Forecast Data |
2022 - 2030 |
| Segments Covered |
By Product Type, By Technology, By Indication, By End-User, And By Geography
|
| Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
Medtronic PLC, Cardiosonic, Inc., Kona Medical, Inc., Abbott Laboratories, Ablative Solutions, Inc., Renal Dynamics, Mercator MedSystems, Inc., ReCor Medical, Inc., Boston Scientific Corp., and Symple Surgical, Inc. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Renal Denervation Market Growth Factors
Availability of improved and alternative technology, such as micro-infusion, for renal denervation systems and better healthcare infrastructures in emerging economies are also expected to enhance market growth. For instance, Mercator MedSystem’s micro-infusion based renal denervation system reduces the blood pressure in patients, by delivering to its agents at a specific site to denervate the renal artery.
Renal Denervation Market Insights
In 2013, according to the Centers for Disease Control and Prevention (CDC), over 3.6lakh people in the U.S. died because of high blood pressure. The occurrence of hypertension has augmented from 17,307 per 100,000 in 1990 to 20,525 per 100,000 in 2015. However, the renal denervation therapy has also shown a optimistic result in minimizing hypertension. Consequently, the advantages offered by such therapies, for instance reduced treatment time, higher safety, and permanent effects are boosting the market growth. Moreover, technological advancement in renal denervation devices is likely to drive the market.
Renal Denervation Market Segmentation
The global renal denervation market is segmented based on product type, technology, indication, end-user, and geography.
Renal Denervation Market By Product Type
- Symplicity
- Enlightn
- Vessix
- Paradise
- Iberis
- Others
Renal Denervation Market By Technology
- Radiofrequency
- Ultrasound
- Micro-Infusion
Renal Denervation Market By Indication
- Hypertension
- Heart Failure
- Diabetes
- Renal Failure
Renal Denervation Market By End-User
- Hospitals
- Specialty Clinics
- Others
Renal Denervation Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Renal Denervation Market Regional Analysis
In 2021, Europe led the renal denervation market in terms of regions and is anticipated to maintain the dominance even during the forecast period. North America renal denervation market is projected to follow Europe, in terms of revenue generation, during the forecast period due to the increasing number of filings for FDA approvals in the U.S. Rising occurrence of uncontrolled hypertension is also one of the key factors responsible for the North America renal denervation market growth. Asia-Pacific renal denervation market is anticipated to experience the fastest growth over the forecast period owing to rising cases of obesity, diabetes, and other lifestyle related diseases. Also, the presence of a large target population base in developing economies like China and Japan are the main drivers for the market growth in Asia-Pacific region.
Renal Denervation Market Players
The key players catering to the global renal denervation market are Medtronic PLC, Cardiosonic, Inc., Kona Medical, Inc., Abbott Laboratories, Ablative Solutions, Inc., Renal Dynamics, Mercator MedSystems, Inc., ReCor Medical, Inc., Boston Scientific Corp., and Symple Surgical, Inc. The global players are continuously investing in R&D activities and innovating to have updated technology-based product portfolio to attract more and more business opportunity from the emerging nation such as that in Asia Pacific countries.
In April 2021, Medtronic collaborated with Surgical Theater, a developer of technology for patients based on fighter aircraft flight simulation. As a result of this collaboration, Medtronic will integrate the Surgical Theater's SyncAR Augmented Reality technology with StealthStation S8 Surgical Navigation System, allowing neurosurgeons to use real-time AR technology to improve visualisation during difficult cranial surgery.
CHAPTER 1. Industry Overview of Renal Denervation Market
1.1. Definition and Scope
1.1.1. Definition of Renal Denervation
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Renal Denervation Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Renal Denervation Market By Product Type
1.2.3. Renal Denervation Market By Technology
1.2.4. Renal Denervation Market By Indication
1.2.5. Renal Denervation Market By End-User
1.2.6. Renal Denervation Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Renal Denervation Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Renal Denervation Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Renal Denervation Market By Product Type
4.1. Introduction
4.2. Renal Denervation Revenue By Product Type
4.2.1. Renal Denervation Revenue (USD Million) and Forecast, By Product Type, 2018-2030
4.2.2. Symplicity
4.2.2.1. Symplicity Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.3. Enlightn
4.2.3.1. Enlightn Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.4. Vessix
4.2.4.1. Vessix Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.5. Paradise
4.2.5.1. Paradise Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.6. Iberis
4.2.6.1. Iberis Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.7. Others
4.2.7.1. Others Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 5. Renal Denervation Market By Technology
5.1. Introduction
5.2. Renal Denervation Revenue By Technology
5.2.1. Renal Denervation Revenue (USD Million) and Forecast, By Technology, 2018-2030
5.2.2. Micro-Infusion
5.2.2.1. Micro-Infusion Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.3. Ultrasound
5.2.3.1. Ultrasound Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.4. Radiofrequency
5.2.4.1. Radiofrequency Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 6. Renal Denervation Market By Indication
6.1. Introduction
6.2. Renal Denervation Revenue By Indication
6.2.1. Renal Denervation Revenue (USD Million) and Forecast, By Indication, 2018-2030
6.2.2. Hypertension
6.2.2.1. Hypertension Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.3. Heart Failure
6.2.3.1. Heart Failure Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.4. Diabetes
6.2.4.1. Diabetes Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.5. Renal Failure
6.2.5.1. Renal Failure Market Revenue (USD Million) and Growth Rate (%), 2018-2030 BFSI
CHAPTER 7. Renal Denervation Market By End-User
7.1. Introduction
7.2. Renal Denervation Revenue By End-User
7.2.1. Renal Denervation Revenue (USD Million) and Forecast, By End-User, 2018-2030
7.2.2. Hospitals
7.2.2.1. Hospitals Market Revenue (USD Million) and Growth Rate (%), 2018-2030
7.2.3. Specialty Clinics
7.2.3.1. Specialty Clinics Market Revenue (USD Million) and Growth Rate (%), 2018-2030
7.2.4. Others
7.2.4.1. Others Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 8. North America Renal Denervation Market By Country
8.1. North America Renal Denervation Market Overview
8.2. U.S.
8.2.1. U.S. Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
8.2.2. U.S. Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
8.2.3. U.S. Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
8.2.4. U.S. Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
8.3. Canada
8.3.1. Canada Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
8.3.2. Canada Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
8.3.3. Canada Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
8.3.4. Canada Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
8.4. North America PEST Analysis
CHAPTER 9. Europe Renal Denervation Market By Country
9.1. Europe Renal Denervation Market Overview
9.2. U.K.
9.2.1. U.K. Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
9.2.2. U.K. Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
9.2.3. U.K. Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
9.2.4. U.K. Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
9.3. Germany
9.3.1. Germany Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
9.3.2. Germany Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
9.3.3. Germany Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
9.3.4. Germany Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
9.4. France
9.4.1. France Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
9.4.2. France Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
9.4.3. France Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
9.4.4. France Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
9.5. Spain
9.5.1. Spain Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
9.5.2. Spain Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
9.5.3. Spain Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
9.5.4. Spain Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
9.6. Rest of Europe
9.6.1. Rest of Europe Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
9.6.2. Rest of Europe Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
9.6.3. Rest of Europe Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
9.6.4. Rest of Europe Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Renal Denervation Market By Country
10.1. Asia Pacific Renal Denervation Market Overview
10.2. China
10.2.1. China Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
10.2.2. China Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
10.2.3. China Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
10.2.4. China Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
10.3. Japan
10.3.1. Japan Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
10.3.2. Japan Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
10.3.3. Japan Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
10.3.4. Japan Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
10.4. India
10.4.1. India Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
10.4.2. India Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
10.4.3. India Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
10.4.4. India Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
10.5. Australia
10.5.1. Australia Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
10.5.2. Australia Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
10.5.3. Australia Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
10.5.4. Australia Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
10.6. South Korea
10.6.1. South Korea Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
10.6.2. South Korea Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
10.6.3. South Korea Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
10.6.4. South Korea Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
10.7.2. Rest of Asia-Pacific Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
10.7.3. Rest of Asia-Pacific Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
10.7.4. Rest of Asia-Pacific Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Renal Denervation Market By Country
11.1. Latin America Renal Denervation Market Overview
11.2. Brazil
11.2.1. Brazil Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
11.2.2. Brazil Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
11.2.3. Brazil Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
11.2.4. Brazil Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
11.3. Mexico
11.3.1. Mexico Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
11.3.2. Mexico Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
11.3.3. Mexico Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
11.3.4. Mexico Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
11.4. Rest of Latin America
11.4.1. Rest of Latin America Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
11.4.2. Rest of Latin America Renal Denervation Revenue (USD Million) and Forecast By, 2018-2030
11.4.3. Rest of Latin America Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
11.4.4. Rest of Latin America Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Renal Denervation Market By Country
12.1. Middle East & Africa Renal Denervation Market Overview
12.2. GCC
12.2.1. GCC Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
12.2.2. GCC Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
12.2.3. GCC Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
12.2.4. GCC Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
12.3. South Africa
12.3.1. South Africa Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
12.3.2. South Africa Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
12.3.3. South Africa Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
12.3.4. South Africa Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Renal Denervation Revenue (USD Million) and Forecast By Product Type, 2018-2030
12.4.2. Rest of Middle East & Africa Renal Denervation Revenue (USD Million) and Forecast By Technology, 2018-2030
12.4.3. Rest of Middle East & Africa Renal Denervation Revenue (USD Million) and Forecast By Indication, 2018-2030
12.4.4. Rest of Middle East & Africa Renal Denervation Revenue (USD Million) and Forecast By End-User, 2018-2030
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Renal Denervation Market
13.1. Renal Denervation Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Renal Denervation Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Medtronic PLC
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Million), 2021
14.1.3.2. Medtronic PLC 2021 Renal Denervation Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Cardiosonic, Inc.
14.3. Kona Medical, Inc.
14.4. Abbott Laboratories
14.5. Ablative Solutions, Inc.
14.6. Renal Dynamics
14.7. Mercator MedSystems, Inc.
14.8. ReCor Medical, Inc.
14.9. Boston Scientific Corp.
14.10. Symple Surgical, Inc.
